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Abstract
Background: There is an emerging literature on the existence and effect of industry relationships on physician and
researcher behavior. Much less is known, however, about the effects of these relationships and other conflicts of interest
(COI) on clinical practice guideline (CPG) development and recommendations. We performed a systematic review of the
prevalence of COI and its effect on CPG recommendations.
Methodology/Principal Findings: We searched Medline (1980 to March, 2011) for studies that examined the effect of COI
on CPG development and/or recommendations. Data synthesis was qualitative. Twelve studies fulfilled inclusion criteria; 9
were conducted in the US. All studies reported on financial relationships of CPG authors with the pharmaceutical industry; 1
study also examined relationships with diagnostic testing and insurance companies. The majority of guidelines had authors
with industry affiliations, including consultancies (authors with relationship, range 6–80%); research support (4–78%);
equity/stock ownership (2–17%); or any COI (56–87%). Four studies reported multiple types of financial interactions for
individual authors (number of types per author: range 2 to 10 or more). Data on the effect of COI on CPG recommendations
were confined to case studies wherein authors with specific financial ties appeared to benefit from the related CPG
recommendations. In a single study, few authors believed that their relationships influenced their recommendations. No
studies reported on intellectual COI in CPGs.
Conclusions/Significance: There are limited data describing the high prevalence of COI among CPG authors, and only case
studies of the effect of COI on CPG recommendations. Further research is needed to explore this potential source of bias.
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Introduction
Since the emergence of the concept of evidence-based medicine
[1], healthcare providers have sought ways to synthesize evidence
into formats and products that are both valid and readily
implemented into routine practice. According to the Institute of
Medicine (IOM) 2008 report entitled Knowing What Works in
Healthcare [2]: ‘‘Decisions about the care of individual patients
should be based on the conscientious, explicit, and judicious use of
the current best evidence on the effectiveness of clinical services.’’
Clinical practice guidelines (CPGs) are an important tool for
achieving optimal patient care, and the recently updated definition
of CPGs is ‘‘statements that include recommendations intended to
optimize patient care that are informed by a systematic review
of evidence and an assessment of the benefits and harms of
alternative care options’’ [3]. Practice guidelines are increasingly
common and can influence a large number of healthcare providers
and patients [4], so their quality is critically important. There are
data to suggest that CPGs improve processes of care [4–6]
although data on the effectiveness of CPGs on health outcome are
sparse and conflicting [6,7].
Conflict of interest (COI) is one important potential source of
bias in the development of CPGs. A COI is a set of conditions in
which professional judgment concerning a primary interest (such
as the health and well being of a patient or the validity of research),
is unduly influenced by a secondary interest [8]. The secondary
interests may be financial or nonfinancial. Bias almost always
results in an overestimation of benefit and an underestimation of
harm [9], and therefore biased CPGs can have profound
implications for health care and ultimately patient outcomes.
There is an emerging literature on the extent of COI, specifically
industry relationships, in clinical research [10–17], and emerging
empirical data suggest that financial relationships of the author or
sponsor with industry are associated with study outcomes [10–
12,17] or decisions [16] favorable to the industry.
Although financial interests are often the most obvious,
intellectual interests are increasingly recognized and may be
powerful motivators for researchers, systematic reviewers, and
guideline authors. Intellectual COI has been defined as ‘‘academic
activities that create the potential for an attachment to a specific
point of view that could unduly affect an individual’s judgment
about a specific recommendation’’ [18]. Intellectual interests
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from publication and the acquisition of research funding. Such
interests are appropriate in themselves, but may conflict with the
interests of research subjects and patients [19]. Levinsky
compared financial to nonfinancial COI and described the latter
as ‘‘more subtle yet more pervasive and [they] cannot be
eliminated [19].’’ According to the American College of
Cardiology Foundation and the American Heart Association
[20] nonfinancial benefits from participation in clinical research
trials include career advancement, fulfillment of a desire to do
good, opportunity to publish, notoriety, invitations to present at
meetings, future success in obtaining grant funding for research,
research prizes, professional accolades for positive outcomes, and
increased sense of self worth.
The objectives of this systematic review were to describe the
extent of COI, both financial and intellectual, in CPGs and to
examine the effect of COI on recommendations within CPGs.
Outlining what is known as well as the gaps in evidence will help
physicians and clinical researchers to: 1) critically appraise CPGs;
2) demand guidelines from their professional societies and other
organizations that make every effort to disclose COI and minimize
bias; 3) be cognizant of what is unknown with respect to this
potential source of bias; and 4) to seek to reduce gaps in knowledge
with future research.
Methods
Searching
We searched Medline (1980 to Week 4 March, 2011) for studies
that examined the prevalence and effect of COI on the
development and/or conclusions of CPGs, using the definition
of CPG published by the Institute of Medicine [3]. Search terms
included conflict of interest, drug industry, research support, and
guidelines (clinical and practice), and Medical Subject Headings
(MeSH) were combined with text words (see Table S1 for the
search strategy). We also reviewed reference lists of included
studies for additional citations. We did not restrict our search by
language of publication.
Selection
Studies were included if they examined either: 1) the prevalence
of conflict of interest, industry relationships, funding, or sponsor-
ship in CPGs or among guideline panel members and authors, or
2) the effect of such conflicts on guideline recommendations. CPGs
could either focus on treatment or prevention interventions, or the
use of diagnostic tests. Two authors (SLN and HH) independently
identified potential studies from the literature search and
consensus on inclusion was achieved. If consensus could not be
reached between these two reviewers, a third coauthor was
consulted (BUB) and consensus was achieved.
Data Abstraction
One reviewer abstracted data into a predefined template that
included domains for the CPG sponsor and clinical focus, study
design, methods for data collection, prevalence and type of COI
for CPGs and CPG authors, and data on the association between
COI disclosures and recommendations. The resulting evidence
tables were reviewed for accuracy by a second author. We did not
perform quality assessment of the included studies because,
although quality assessment tools are available for observational
studies [21], we felt that formal assessment would not contribute to
our ability to discriminate among studies in view of their
descriptive, noncomparative designs.
Data Synthesis
We undertook a qualitative synthesis across included studies
because there was substantial heterogeneity with respect to
characteristics and outcomes, making a meta-analysis inappropriate.
Results
Twelve studies fulfilled inclusion criteria (Table 1) after 208 full-
text publications were reviewed (Supplemental Information Figure
S1). Nine studies were conducted in the US [13–15,22–27], one in
Greece [28], one in Australia [29], and one was international [30].
All studies examined COI in relatively recent guidelines, although
one study searched for guidelines dating back to 1979 [28]. Several
studies examined guidelines across a variety of specialties
[14,15,22,28,29], while others focused on one or more guidelines
within a medical specialty [13,23–27,30]. All included studies
examined different cohorts of CPGs; no studies examined
overlapping CPGs. Most studies focused on treatment or
prevention CPGs, while two focused exclusively on diagnosis
[26,27].
Included studies either examined COI at the level of the CPG
or at the level of the individual authors of CPGs (Table S2). There
were few data on the percentage of CPGs that disclosed
information on COI, and the available data suggested that many
CPGs do not disclose author COI. Choudhry and colleagues
reported that the majority of CPGs (42 of 44) published between
1991 and 1999 did not declare authors’ COI [15]. Papanikolaou
and colleagues similarly found that only a small percentage (3.7%)
of 191 CPGs published in 1999 disclosed COI [28]. In a 2004
review of CPGs in the National Guideline Clearinghouse
TM
(www.guideline.gov), 42% of CPGs included information on
author COI [22]. In the most recent study, 79% of CPGs made
no mention of possible competing interests of members [29].
Among CPGs that disclosed COI, the majority involved authors
with one or more conflicts. Holloway and colleagues reported that
92% of 50 American Academy of Neurology CPGs had a least one
author with a COI and 77% of guideline authors had one or more
reported conflicts [13]. Nature published results of a 2004 survey of
CPGs within the National Guideline Clearinghouse
TM that
contained pharmacotherapeutic recommendations [22]. Of more
than 200 guidelines, only 90 contained information on an
individual author’s COI, and of those, only 31 were free of
industry influence. More than one-third of guideline panels
included at least one member who gave seminars on behalf of a
relevant drug company. The author of this study expressed
concern that guideline authors may underreport COI and
reported that the Center for Science in the Public Interest
examined the disclosure statements on randomly chosen blood
pressure guidelines, and found that several authors did not report
relevant sources of research funding [22]. In another study,
physicians who produced CPGs had a higher frequency of various
payments from industry than physicians who did not develop
guidelines (odds ratio 1.41, 95% confidence interval, 1.04 to 1.91)
[14].
In a now dated review of CPGs published between 1991 and
1999 on common adult diseases [15], 87% of guideline authors
acknowledged some form of interaction with the pharmaceutical
industry when questioned on a survey, although most of the CPGs
did not report author disclosures (42 of 44 CPGs). On average,
authors of treatment guidelines interacted with 10.5 different drug
companies and 59% of authors had relationships with companies
whose products were specifically considered in those guidelines.
Frequent relationships were reported in the three other studies
reporting overall percentages of CPG authors with industry
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cancer management) [30], and 77% (neurology) [13].
All 12 included studies reported financial relationships between
guideline authors and the pharmaceutical industry. In addition, a
review of the development process of Lyme disease guidelines by
the Infectious Diseases Society of America reported relationships
between guideline authors and developers of Lyme disease
diagnostic test kits and vaccines as well as insurance companies
reviewing disability claims related to Lyme disease [25].
Specific types of financial relationships were reported in nine
studies (Table S2), the most common being research or salary
support and remuneration for consultation or serving on speaker
bureaus. The types of financial interests reported by CPG
authors were similar across studies. No study examined
intellectual COI such as academic advancement, relationships
to specialty societies, or previously published study findings or
opinions.
We identified no empirical data on the effect of COI on
recommendations in CPGs. A survey of perceptions about COI
reported that only 7% of CPG authors believed that their own
financial relationships with industry influenced their personal
conclusions. On the other hand, 19% of CPG authors believed
that industry relationships influenced the recommendations of
colleagues [15].
One study reported that 42% of CPG authors performed the
clinical procedure examined in the CPGs in their practice, with
33% of their clinical effort devoted to such procedures [13].
Several studies noted specific examples whereby the recommen-
Table 1. Characteristics of included studies.
Author
Year
Country
CPG Sponsor
Clinical Focus of Guidelines
No. CPGs
No. Authors Study Design Methods
Guidelines on treatment or prevention
Buchan
2010 [29]
Australia
National Institute of Clinical Studies
Various clinical conditions
313
NR
Retrospective single-
group cohort
Systematic search for Australian CPGs produced or
reviewed between 2003 and 2007
Campbell
2007 [14]
US
NR
NR
NR
711
Cross-sectional Survey of representative sample of US physicians
Choudhry
2002 [15]
North America
and Europe
CPGs endorsed by North American and
European societies on common adult
diseases published 1991–1999
Various adult diseases
44
NR
Retrospective single-
group cohort study and
cross-sectional survey
Systematic review of Medline to identify CPGs; survey of
CPG authors regarding specific financial interests
Cosgrove
2009 [24]
US
American Psychiatric Association
Schizophrenia, 2004
Bipolar disorder, 2002
Major depressive disorder, 2000, 2005
3
20
Retrospective single-
group cohort
Review of data from US Patent and Trademark Office,
Lexis-Nexis Academic, Medline, other internet search
engines, screening between 1989 and 2004 (DSM-IV was
published in 1994)
Coyne
2007 [23]
US
Kidney and Dialysis Outcomes Quality
Initiative
Anemia in chronic kidney disease
1
NR
Retrospective single-
group cohort
Financial COI disclosed in CPG documents
Hietanen
2009 [30]
International
NR
Management of early breast cancer
1
43
Retrospective single-
group cohort clinical
guidelines in breast
cancer
Searchfor disclosed financialCOI via internet andPubMed;
The Faculty/Program Committee Disclosure Index of
American Society of Clinical Oncology Breast Cancer
Symposium 2007; European Society for Medical Oncology
Holloway
2008 [13]
US
American Academy of Neurology
Neurology, various conditions
50
425
Prospective cross-
sectional study
Survey of CPG authors
Johnson
2009 [25]
US
Infectious Diseases Society of America
Lyme disease, human granulocytic
anaplasmosis, and babesiosis
1
5
Prospective, cross-
sectional study
Attorney general anti-trust investigation into the CPG
development process
Papanikolaou
2001 [28]
International
NR
Various clinical conditions
191
242
Retrospective single-
group cohort
Hand-search of 6 high impact journals for CPGs
published at 5-year intervals between 1979 and 1999
Taylor
2005 [22]
International
NR
CPGs with recommendations on
prescription medications
215
685
Cross-sectional survey Examined all CPGs involving drugs in the National
Guidelines Clearinghouse
TM in 2004
Guidelines on diagnosis
Cosgrove
2006 [26]
US
American Psychiatric Association Manual
for the Diagnosis of Psychiatric Disorders
(DSM-V)
Psychiatry
18
170
Retrospective single-
group cohort
Review of data from US Patent and Trademark Office,
Lexis-Nexis Academic, Medline, other internet search
engines; screening between 1989 and 2004 (DSM-IV was
published in 1994)
Cosgrove
2009 [27]
US
American Psychiatric Association Manual
for the Diagnosis of Psychiatric Disorders
(DSM-V)
Psychiatry
NR
NR
Retrospective single-
group cohort
NR
Abbreviations: COI, conflict of interest; CPG(s), clinical practice guideline(s); DSM, Diagnostic and Statistical Manual for Mental Disorders; NR, not reported; No., number.
doi:10.1371/journal.pone.0025153.t001
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guideline authors (Table S2) [22–25,30].
Two studies examined COI among an expert panel determining
diagnostic criteria for disease. Cosgrove and colleagues reported
on financial ties among developers of the Diagnostic and Statistical
Manual of Mental Disorders (DSM) and reported that 56% (DSM
IV [26]) and 68% (DSM V [27]) of panel members had financial
interests in the pharmaceutical industry.
Discussion
There are few studies describing financial COI for CPG authors
and the available data suggest that there is a high prevalence of
nondisclosure of COI among authors across a variety of clinical
specialties, and a high percentage of CPG authors with disclosures
report COI. We identified no empirical data on the effect of those
conflicts on clinical recommendations within guidelines and no
data on intellectual COI or the role of CPG sponsors in guideline
development.
Many of the studies in this review examined data that are more
than 5 years old, however, and since interest in, and policies
relevant to, COI have changed rapidly in recent years, the data
examined herein may have limited applicability to CPGs produced
in 2011. Since the publication of the studies in this review, marked
changes have occurred in awareness of the frequency and potential
effects of COI. Physician professional organizations, medical
editors, public policy makers, governmental agencies, and industry
are all working to address COI among their respective constituents
and in their products, including CPGs [31–38]. This increased
awareness has led to more frequent, transparent, and complete
disclosure of financial relationships by authors and sponsors of
primary studies and CPGs. Of particular importance is the recent
implementation of a uniform, detailed disclosure form by all
journals that are members of the International Committee of
Medical Journal Editors [31,39]. A uniform policy for disclosures
of competing interests among CPG authors should decrease
variation in disclosures, and more importantly, provide both
developers and users of CPGs with appropriate information. In
addition, the Physician Payment Sunshine provisions, signed into
law in March, 2010 as part of the Patient Protection and
Affordable Care Act of 2009, require that the U.S. government set
up a public database listing any payment or gift to doctors and
teaching hospitals valued at more than $10. A publicly available
database with this information will be available in 2013 [32].
Furthermore, a recent report by the IOM in the U.S. may provide
guidance for developers and publishers of CPGs [40,41]. Formal
processes for translating a body of evidence into recommendations
in CPGs (such as the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) Working Group) may
diminish the effect of COI among guideline panel members on
recommendations although data are not yet available to affirm this
[42]. Thus in 2011, there is certainly increasing attention paid to
COI, but data are lacking on the current prevalence of COI in
recently developed CPGs and on the effects of COI on
recommendations.
We noted significant variation in the prevalence of COI among
CPG authors, which might be explained by different policies
across journals and organizations sponsoring CPGs, by variations
in culture and funding of CPGs among specialties, and by the
different time periods for development of guidelines examined in
studies included in this review.
There are a large number of gaps in the available literature. We
were unable to identify any studies that examined the actual effect
(not just the prevalence) of industry affiliations or support on
recommendations in CPGs. This is perhaps not surprising as it is
very difficult to qualify, let alone quantify, the effects in
observational studies of industry relationships on conclusions
because confounders as well as of other sources of bias in addition
to COI. In addition, observational data on COI cannot, of course,
prove that conflicts are causally related to specific recommenda-
tions. Nonetheless, observational data can be used to explore
relationships and to generate hypotheses on the extent and
direction of the influences exerted by specific conflicts on
recommendations in CPGs. The frequent lack of temporal data
within financial disclosures also makes it difficult to explore
associations between COI and CPG recommendations.
We identified no data on the nature, extent, and effect of
intellectual COI. This type of COI is much more difficult to define
and quantify, let alone examine its effect on specific recommen-
dations. It has been suggested, however, that intellectual COI may
be a far more important influence on guideline developer decision
making than financial interests [19,43]. Few CPG organizations
are reporting this type of COI, although there is some interest in
developing policies addressing this issue [18].
In addition, we found no evidence on the role of sponsors or
funders in CPG development and decision making. The IOM
Panel reported that medical specialty societies (40.9%) and
professional associations (17.4%) are the dominant funders of
CPGs contained within the National Guideline Clearinghouse
TM
[44]. These institutions could potentially be a major source of bias
in the generation of CPG recommendations if they do not have
adequate and transparent quality controls and processes in place.
The sponsor may be in a position to influence the selection of CPG
topics, the identification and evaluation of the body of evidence,
the process for deriving recommendations from the evidence, and
dissemination of the CPGs [44]. The influence of industry
sponsorship or author interests may be particularly important
when data for CPG recommendations are lacking, as is frequently
the case [45].
Limitations
There was heterogeneity of methodologies used for the
assessment of COI, thus we were unable to perform a quantitative
synthesis (meta-analysis) of the data. Some studies examined
disclosures reported by CPG authors, while other studies reported
author financial interests gleaned from internet searches. Classi-
fication of COI and methods for reporting data also differed across
studies.
A further limitation of the available data was that the accuracy
of disclosures, both completeness and specific relationships
reported, was not assessed in the studies reviewed herein. Self
report by guideline authors may be inaccurate, as suggested by
data on disclosures in primary research studies [46] and responses
rates were low when surveying CPG authors on their COI [15].
Some of the studies in this review explored financial relationships
for CPG authors in addition to information provided in author
disclosures [24,26,30], but comparisons were not made between
information from these two sources. Internet searches for COI
may also be incomplete or inaccurate as they will likely not reveal
all important funders and sponsors, and certainly will not reveal
stock and other equity relationships.
In addition to the limitations imposed by the available data, our
study had limitations in methodology. First, we searched Medline
for studies for inclusion, and it is possible that other bibliographic
databases might have provided additional studies. We felt,
however, that other databases would likely have very low
incremental yield given that we focused on English-language
CPGs, performed an extensive MeSH and text work search, and
Conflict of Interest in Practice Guidelines
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papers. We searched for non-English studies indexed in Medline
and found none, suggesting that most of the relevant literature is in
the English language and thus more likely to be identified in
Medline. Second, we did not perform dual independent review of
data abstraction; rather a second author checked all abstractions.
Future Research
Much additional research is needed on the nature and impact of
COI in the development of CPGs. Research is needed on the
effect of CPG authors’ financial and intellectual interests on their
decision processes, their assessment of the quality and inclusion of
specific studies in the body of evidence, their assessment of the
direction and strength of the evidence, and the translation of
evidence into recommendations. The accuracy of disclosures of
financial interests by CPG authors needs to be examined. Further
work is needed as to whether formal processes such as GRADE
reduce bias in guideline development associated with COI among
the CPG authors [42]. Work is also needed on how disclosed COI
affect readers’ perceptions. Research is needed on the potential
effects of intellectual COI. The role of sponsors in the selection of
guideline panel members and in the processes and generation of
recommendations needs to be explored, along with the risk for bias
in CPG recommendations due to specialty and other professional
and personal interests. Little is known about how biomedical
journal readers interpret disclosures and whether and/or how they
actually apply the information [47–50]. Such empirical data will
then be available to guide future policies on optimal processes for
collection of accurate disclosures and the subsequent management
of disclosed conflicts, as well as methods for presenting meaningful
information to users of CPGs.
CPGs are designed to be widely used, to impact healthcare
provider practice, to have positive effects on economic efficiency,
and to ultimately improve patient outcomes. Until such time as
CPGs uniformly report accurate and relevant disclosures, there are
data available on the relationships between various types of COI
and guideline recommendations, and such relationships are
appropriately managed, the user of CPGs is at a severe
disadvantage in evaluating the quality of a given CPG. For now,
users need to critically appraise CPGs considered for implemen-
tation, read disclosures and consider how they may have
influenced recommendations, and seek to move forward research
on unanswered questions.
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